Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus ICE for Relapsed/Refractory Gray Zone Lymphoma
NCT04860674Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in gray zone lymphoma (GZL), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
gray zone lymphoma (GZL)
Beyond the preview
Go deeper on NCT04860674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04860674.